During the September 2023 “57th Congress of the European Societies of Toxicology (EUROTOX 2023): TOXICOLOGY - MULTIDISCIPLINARY SCIENCE LEADING TO SAFER AND SUSTAINABLE LIFE”, some posters on nitrosamine toxicology were presented (you can find the abstracts back in Toxicology Letters from Elsevier):
P03-22 Sensitivity of primary human hepatocytes and HepG2 cells for genotoxicity testing of N-nitrosamines in the in vitro alkaline comet assay (from the Fraunhofer Institute, cf. EMA funded Mutamind project)
[Redirecting]
P24-41 Nitrosamines impurities carcinogenicity assessment –regulatory requirements, challenges and recommendations (from the consulting firm ToxMinds)
[Redirecting]
P22-29 Spherical harmonic based clustering as a NAM to classify carcinogenic potency of N-nitrosamines (from Harmonic pharma, Loria and ERBC, France)
[Redirecting]
P24-05: Nitrosamines in medicinal products: a regulatory overview (from CBG-MEB; the author Ira Koval is a member of EMA NcWP NS OEG)
[Redirecting]
As the abstracts are interesting but quite brief, I was wondering if any of the forum members visited the conference last week and would care to give some insights on take-aways from the conference with regards to nitrosamines?
Also this year during the September 2024 “58th Congress of the European Societies of Toxicology (EUROTOX 2024)" some posters on nitrosamine toxicology were presented (you can find the abstracts back in Toxicology Letters from Elsevier):
Chakravarti, S., & Saiakhov, R. (2024). P05-26 A comprehensive set of structural keys for N-Nitrosamine fingerprinting and determining surrogate relevance in Carcinogenic Potency Assessments. Toxicology Letters, 399, S141–S142. Redirecting
van Rossum, P., Gernaat, A., Hoogenboom-Geijer, M., Roberts, D., Brandsma, I., Moelijker, N., & Hendriks, G. (2024). P02-08 Using ToxTracker and DNA Repair-Deficient Cell Lines to Determine the Genotoxic Mode of Action of N-Nitrosamines. Toxicology Letters, 399, S107–S107. Redirecting
Bringezu, F., Simon, S., & Dieckhoff, J. (2024). P13-23 A comparative analysis of the ability of various S9 compositions to metabolically activate N-nitrosamines to mutagens in the bacterial reverse mutation test. Toxicology Letters, 399, S219–S219. Redirecting
The Toxys poster (P02-08) shows optimization of in vitro metabolization of nitrosamines with hamster S9 and starting work on exploring DNA damage repair related to larger nitrosamines.
The Merck poster (P13-23) reminds again that increasing S9 concentration can lead to cytotoxicity during the Ames test, reconforming some doubts on the overall improvement of the assay by increasing from 10% to 30%. This poster also links back to:
Bringezu, F., & Simon, S. (2022). Salmonella typhimurium TA100 and TA1535 and E. coli WP2 uvrA are highly sensitive to detect the mutagenicity of short Alkyl-N-Nitrosamines in the Bacterial Reverse Mutation Test. Toxicology Reports, 9, 250–255. Redirecting
Dieckhoff, J., Bringezu, F., & Simon, S. (2024). Metabolic activation of short-chain alkyl N-nitrosamines using Aroclor 1254 or phenobarbital/beta-naphthoflavone-induced rat or hamster S9 – A comparative analysis. Toxicology Reports, 12, 215–223. Redirecting.
Did anyone here attend Eurotox 2024 and has more details on the posters, particularly P02-08?